Table 1. Main features of the follow-up study.
| Patient | Antibiotic | Mode of action/ Antimicrobial effect | Pathology | Sampling date | Samples |
| A | Moxifloxacin | Cell replication inhibitor/ Bactericidal | Bronchitis, pneumonia | day0-before AB | A_before |
| day3-during AB | A3_D | ||||
| day6-during AB | A6_D | ||||
| day10-during AB | A10_D | ||||
| day13-during AB | A13_D | ||||
| 3 days after AB | A_after | ||||
| B | Clindamycin | Protein synthesis inhibitor/ Bacteriostatic | Erysipelas | day0-before AB | B_before |
| day2-during AB | B2_D | ||||
| day5-during AB | B5_D | ||||
| day6-during AB | B6_D | ||||
| 28 days after AB | B_after | ||||
| C | Cefazolin/ Ampicillin/ Sulbactam | Cell envelop synthesis inhibitor/ Bactericidal | Infection pacemaker | day0-before AB | C_before |
| day3-during AB | C3_D | ||||
| day6-during AB | C6_D | ||||
| day10-during AB | C10_D | ||||
| 3 days after AB | C_after | ||||
| D | Amoxicillin | Cell envelop synthesis inhibitor/ Bactericidal | Chronic sinusitis maxillans | day0-before AB | D_before |
| day3-during AB | D3_D | ||||
| 7 days after AB | D_after |
AB, antibiotic; D, during the treatment.